Net debt/EBITDA spoločnosti Kazia Therapeutics

Aká je hodnota metriky Net debt/EBITDA spoločnosti Kazia Therapeutics?

Hodnota metriky Net debt/EBITDA spoločnosti Kazia Therapeutics Limited je 0.58

Aká je definícia metriky Net debt/EBITDA?

The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.

The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.

Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization

Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.

Čomu sa venuje spoločnosť Kazia Therapeutics?

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Firmy s metrikou net debt/ebitda podobnou spoločnosti Kazia Therapeutics

  • Hodnota metriky Net debt/EBITDA spoločnosti Johnson Service PLC je 0.58
  • Hodnota metriky Net debt/EBITDA spoločnosti Facedrive je 0.58
  • Hodnota metriky Net debt/EBITDA spoločnosti Steer Technologies Inc je 0.58
  • Hodnota metriky Net debt/EBITDA spoločnosti KNT je 0.58
  • Hodnota metriky Net debt/EBITDA spoločnosti Aris Gold je 0.58
  • Hodnota metriky Net debt/EBITDA spoločnosti Generix SA je 0.58
  • Hodnota metriky Net debt/EBITDA spoločnosti Kazia Therapeutics je 0.58
  • Hodnota metriky Net debt/EBITDA spoločnosti Auto Trader Plc je 0.58
  • Hodnota metriky Net debt/EBITDA spoločnosti Sinotrans je 0.58
  • Hodnota metriky Net debt/EBITDA spoločnosti Copper Lake Resources je 0.58
  • Hodnota metriky Net debt/EBITDA spoločnosti Core One Labs je 0.58
  • Hodnota metriky Net debt/EBITDA spoločnosti Oeneo SA je 0.58
  • Hodnota metriky Net debt/EBITDA spoločnosti Oeneo SA je 0.58